Oral minoxidil for late alopecia in cancer survivors
Breast Cancer Research and Treatment · 2024
DOI: 10.1007/s10549-024-07440-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Alyce Mei-Shiuan Kuo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Alopecia, Minoxidil, Cancer Survivors. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Cancer Institute of the National Institutes of Health, Swiss National Science Foundation.
Abstract (Originalsprache)
PURPOSE: Late alopecia, defined as incomplete hair regrowth > 6 months following cytotoxic chemotherapy or > 6 months from initiation of endocrine therapy, negatively impacts quality of life and may affect dose intensity of adjuvant therapy. This study investigates the effect of oral minoxidil in women with chemotherapy and/or endocrine therapy-induced late alopecia. METHODS: The rate of clinical response was assessed by standardized photography and quantitated with trichoscopy. RESULTS: Two hundred and sixteen patients (mean age 57.8 ± 13.7) were included. The most common cancer diagnosis was breast, in 170 patients (79.1%). Alopecia developed after chemotherapy in 31 (14.4%) patients, endocrine monotherapy in 65 (30.1%) patients, and chemotherapy followed by endocrine therapy in 120 (55.6%) patients. In 119 patients, standardized photography assessments were used to determine clinical change in alopecia after a median of 105 (IQR = 70) days on oral minoxidil and revealed improvement in 88 (74%) patients. Forty-two patients received quantitative trichoscopic assessments at baseline and at follow-up after a median of 91 (IQR = 126) days on oral minoxidil. Patients had clinically and statistically significant increases in frontal hair shaft density (from 124.2 hairs/cm2 at initial to 153.2 hairs/cm2 at follow-up assessment, p = 0.008) and occipital shaft density (from 100.3 hairs/cm2 at initial to 123.5 hairs/cm2 at follow-up assessment. p = 0.004). No patients discontinued oral minoxidil due to adverse events. CONCLUSIONS: Overall, oral minoxidil was well tolerated by patients and may benefit both frontal and occipital late alopecia in cancer survivors treated with cytotoxic and/or endocrine therapy by increasing hair shaft and follicle density.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Ludwig Collaborative and Swim Across America Laboratory, Human Oncology and Pathogenesis Program, Department of Medicine, MSKCC, Parker Institute for Cancer Immunotherapy, New York, NY, USA.
- Breast Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Canfield Scientific, Inc., Parsippany, NJ, USA.
- Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, NY, USA.
- Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Mario.Lacouture@nyulangone.org.
Förderung
- National Cancer Institute of the National Institutes of Health
- Swiss National Science Foundation
Zitieren
APA
Kuo, A. M., Reingold, R. E., Ketosugbo, K. F., Pan, A., Kraehenbuehl, L., Dusza, S., Gajria, D., Lake, D. E., Bromberg, J. F., Traina, T. A., Fornier, M. N., Gucalp, A., D'Alessandro, B. M., Rotemberg, V., Dauscher, M., Shapiro, J., Goldfarb, S. B., Markova, A., & Lacouture, M. E. (2024). Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07440-5
Vancouver
Kuo AM, Reingold RE, Ketosugbo KF, Pan A, Kraehenbuehl L, Dusza S, et al. Oral minoxidil for late alopecia in cancer survivors. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07440-5
BibTeX
@article{Kuo2024,
author = {Kuo, Alyce Mei-Shiuan and Reingold, Rachel E and Ketosugbo, Kwami F and Pan, Alexander and Kraehenbuehl, Lukas and Dusza, Stephen and Gajria, Devika and Lake, Diana E and Bromberg, Jacqueline F and Traina, Tiffany A and Fornier, Monica N and Gucalp, Ayca and D'Alessandro, Brian M and Rotemberg, Veronica and Dauscher, Megan and Shapiro, Jerry and Goldfarb, Shari B and Markova, Alina and Lacouture, Mario E},
title = {Oral minoxidil for late alopecia in cancer survivors},
journal = {Breast Cancer Research and Treatment},
year = {2024},
doi = {10.1007/s10549-024-07440-5}
}
EUVIMED